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Perinatal brain damage is one of the leading causes of life long disability.This damage could
be hypoxic–ischemic, inflammatory, or both.This mini-review discusses different interven-
tions aiming at minimizing inflammatory processes in the neonatal brain, both before and
after insult. Current options of anti-inflammatory measures for neonates remain quite
limited. We describe current anti-inflammatory intervention strategies such as avoiding
perinatal infection and inflammation, and reducing exposure to inflammatory processes.
We describe the known effects of anti-inflammatory drugs such as steroids, antibiotics,
and indomethacin, and the possible anti-inflammatory role of other substances such as
IL-1 receptor antagonists, erythropoietin, caffeine, estradiol, insulin-like growth factor, and
melatonin as well as endogenous protectors, and genetic regulation of inflammation. If suc-
cessful, these may decrease mortality and long-term morbidity among term and pre-term
infants.
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INTRODUCTION
Perinatal brain damage is one of the leading causes of life long dis-
ability, cerebral palsy, seizure disorders, sensory impairment, and
cognitive limitations (1). The insult may be hypoxic–ischemic,
hemorrhagic, inflammatory, or a combination (2). As the evi-
dence for the essential role of inflammation in the pathogenesis
of perinatal brain injury accumulates, inflammation is strongly
recognized as a major cause leading to long-term injury (3).
During inflammation, there is a systemic up-regulation of pro-
inflammatory cytokines and diffuse activation of microglia in
the neonatal brain (2, 3). Microglia enhance injury by express-
ing inflammatory mediators and pro-inflammatory cytokines (4).
Cytokine-activated cells release toxic substances, such as reactive
oxygen species and toxic granules including proteolytic enzymes
and myeloperoxidase (5).
The pro-inflammatory cytokines can activate cytotoxic T
cells, natural killer cells, lymphokine-activated killer cells, which
enhance excessive cellular and tissue damage (5).
This results in cell proliferation, cell differentiation, and cell
death, all causing white matter damage (WMD) and long-term
neurological injury among pre-term and term neonates (2, 4, 5).
Is it possible to control or reduce this damage?
Since early brain injury has major long-term consequences,
efforts should be in limiting this damage in order to reduce
morbidity and mortality (1, 2).
Intuitively, if the neonatal immune system is capable of pro-
ducing an inflammatory response, blockade of inflammatory
cytokines may contribute to prevention of early brain damage.
However, the same cytokines responsible for these unfavorable
effects in the neonatal brain, as a paradox have been attributed to
have beneficial neurotrophic effect (6). Cytokines play a vital role
in elimination of cellular debris, and in growth and repair, thus
contributing to tissue recovery. Activation of glial cells triggers lib-
eration of factors, such as colony-stimulating factor-1, which are
necessary for neuronal survival (6).
This dual effect complicates the task of developing targeted
interventions to reduce inflammatory response (6). A better
understanding and control of inflammatory processes in the pre-
natal, perinatal, and postnatal periods may improve the outcome
of affected babies.
It is clear that there are other processes, which are beyond the
scope of this mini-review that contribute to early neonatal brain
injury. Independent and additive to other insults, hypoglycemia
for example, which is common in newborns, has been associated
with adverse outcomes in term infants, resulting in visual impair-
ment, localization-related epilepsy, and cognitive deficits (7). For
the purpose of this review, we have focused on inflammation-
related damages to the neonatal brain, and did not discuss other
processes.
The objective of this mini-review is to describe current and
future perspectives of management strategies designed to limit
early inflammatory responses and reduce the risk of early brain
injury among term and preterm neonates.
AVOIDING PERINATAL INFECTION AND INFLAMMATION
Chorioamnionitis complicates up to 10% of pregnancies, and
35% of preterm labor (8). It stimulates maternal–fetal pro-
inflammatory cytokine release, which may interfere with glial cell
development and proliferation, at a time in which the brain is
most vulnerable. This damage to the developing fetal nervous sys-
tem increases the risk for adverse long-term neuro-developmental
outcome (8).
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Therefore strategies based in widespread prenatal education
regarding the risks, signs, and symptoms of intra amniotic infec-
tions as well as early detection and treatment of maternal infections
should be implemented (8, 9).
Timely diagnosis and prompt antibiotic treatment of pregnant
women with infection may significantly improve the outcome of
both mother and infant (9).
Prenatal group B streptococcus prophylaxis and prenatal mea-
sures such as the reduction of nosocomial infections by meticulous
hand hygiene, minimizing central line days, and early introduction




Cortisol has an essential role in the modulation of inflammatory
responses. Some preterm infants demonstrate a limited ability to
produce cortisol in response to stress (10). Corticosteroids down-
regulate inflammatory cytokines, which raises the possibility of
cerebral WMD reduction. Should we treat newborn infants with
steroids for improving neurological outcome? Currently steroids
are recommended antenatally but not immediately after birth (11).
Early dexamethasone treatment (before the first week of life),
has been found to be associated with adverse neuro-developmental
outcome, and is no longer recommended (12). In a study con-
ducted by Benders et al., ventilated preterm infants were treated
with hydrocortisone from 1 week of age onward (13). In this study,
ventilator-dependent infants at 1 week of age were considered to
be developing chronic lung disease unless a patent ductus arte-
riosus (PDA) or an infection was demonstrated. No effect was
shown regarding brain growth, measured at term equivalent age,
after treatment with hydrocortisone for chronic lung disease (13).
More data is required before considering early steroidal treatment
in the early neonatal period.
ANTIBIOTICS
Although not specifically prescribed for this purpose, certain
antibiotics appear to have an anti-inflammatory effect beyond
their antibacterial properties (14). Studies have targeted microglial
activation as a therapeutic strategy in models of inflammation
(15). The tetracycline derivatives, minocycline and doxycycline,
which are not routinely used in neonatology have shown to have
protective efficacy in cellular injury via microglial inactivation
(15). Minocycline reported to variably inhibit microglial acti-
vation and to reduce WMD in focal cerebral ischemia in the
immature rat brain (15). Lechpammer et al. provide evidence for
the protective effect of treatment with minocycline serving as a
microglial inactivator when administered over the 96 h time win-
dow following early brain insult in a rat model. Most importantly,
minocycline appears to have protective efficacy against WMD
when administered following the insult. This effect is mediated
via reducing the density of microglia (15) through reducing the
density of the age-specific target cell – the microglia (15).
Post treatment efficacy has important clinical potential, as brain
injury in infants is often detected hours to days after the insult.
Minocycline protection against myelin basic protein loss in WM
was concomitant with a decrease in the density of CD-68-positive
cells suggesting that minocycline-mediated reduction in microglial
cell numbers is a likely mechanism for protection.
However, minocycline may also be acting directly on pre-
oligodendrocytes via interruption of oxidative stress pathways,
blood–brain barrier (BBB) breakdown, and myelin basic protein
degradation (15).
Filipovic et al. studied the mechanism of the neuroprotective
effect of minocycline in co-cultures of microglia and neurons from
human fetal brain during inflammation induced by lipopolysac-
charide (LPS) (16). In neuron/microglial co-cultures, minocycline
treatment prevented activation and proliferation of microglia and
protected neurons as demonstrated by decreased neuronal cell
death. However, the use of tetracyclines, including minocycline,
during tooth development has been shown to cause permanent
tooth discoloration and enamel hypoplasia, and a decrease in bone
growth. Furthermore, emergence of resistant bacteria strains in
neonatal intensive care units (NICU’s) is a major issue limiting
the use of antibiotics in non-infectious scenarios (15, 16).
INDOMETHACIN
Indomethacin is a cyclooxygenase inhibiting agent used for the
treatment of PDA in preterm infants. Reduction in cerebral,
mesenteric and renal blood flow, spontaneous intestinal perfo-
ration, as well as platelet dysfunction are recognized as poten-
tial adverse effects of indomethacin treatment, and are partially
overcome by continuous administration of the drug (17).
Schmidt et al. found that in extremely low birth weight infants,
prophylaxis with indomethacin does not improve the rate of sur-
vival at 18 months, despite the fact that it reduces the frequency of
PDA and severe periventricular and intraventricular hemorrhage
(IVH) (18).
However, Miller et al. showed that in newborns born before
28 weeks gestation, the only neonatal factor associated with a
reduced risk of developing early white matter injury was prolonged
exposure to indomethacin treatment (19).
A randomized trial of prolonged indomethacin treatment is
needed to determine whether indomethacin can reduce white
matter injury and neuro-developmental morbidity.
OTHER THERAPEUTIC INTERVENTIONS
IL-1 RECEPTOR ANTAGONIST
Human neuropathological studies and animal models have
revealed IL-1 is implicated in the cascade leading to brain injury
at different developmental stages (20). Girard et al. have reported
that postnatal administration of IL-1 receptor antagonist in rat
pups, who were exposed perinatally to LPS-induced inflammation,
preserved both motor function and exploratory behavior. They
reported protected stem cell population, prevention of myelin
loss in the internal capsule, and less gliosis in treated animals
(20). Others have demonstrated that prophylactic administration
of IL-1 receptor antagonist to mouse pups, following a peri-
natal inflammatory insult offered significant protection against
bronchopulmonary dysplasia (21).
RECOMBINANT HUMAN ERYTHROPOIETIN
Erythropoietin was shown to have a protective effect against
inflammatory injuries in a broad range of tissues and organs (14).
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A variety of models of neonatal and adult brain injury, highly favor
recombinant human erythropoietin (rhEpo) as a novel, effective
neuroprotective pharmacological agent (14).
Sifringer et al. report that systemic treatment with rhEpo in
a rodent model of brain injury significantly decreased levels of
caspase-1-dependent pro-inflammatory cytokines interleukin-1
and 18 (22). Others reported rhEPO treatment coupled to for-
malin injections, ameliorated neuronal cell death, and normalized
the inflammatory response in rats with pain induced inflam-
matory changes. Treated rats exhibited normal levels of cerebral
blood flow, pain sensitivity, and exploratory behavior compared
to untreated controls (23).
Liu et al. investigated whether Epo and its derivative car-
bamylated erythropoietin (cEpo) could provide protection in
mouse models of periventricular leukomalacia (PVL) induced by
hypoxia–ischemia inflammation. They have found that both Epo
and cEpo treatment decreased microglia activation, oligodendro-
cyte damage, and myelin depletion (24).
The neuroprotective effect of rhEpo has also been shown
in experimental rodent models of hypoxia, hypoxia–ischemia,
excitotoxicity, and neonatal stroke (25). Moreover, an improve-
ment in long-term neurological outcome following neonatal
stroke and hypoxia–ischemia has been reported in Ref. (26).
Even in human studies, neurological improvement attributable
to erythropoietin was observed at postnatal day 7 in term
infants who suffered from moderate to severe perinatal asphyxia
who received erythropoietin, compared to control subjects (27).
The rates of disability at 18 months of age were also lower
in the erythropoietin treated infants (27). Brown et al. found
higher mental developmental scores in preterm infants who were
treated with a higher dose (400 versus 250 U/kg) of rhEpo for
6 weeks (28).
However, following reports of increased mortality (16% ery-
thropoietin versus 9% placebo) in elderly patients after stroke,
there were some concerns regarding safety of high-dose erythro-
poietin (29). The risk of repeated erythropoietin exposure in adult
patients may not apply to the preterm population, for whom the
potential benefits may be profound.
One of the possible mechanisms of its neuro-protective effects
is an anti-inflammatory effect after binding to its receptor
(EPOR), which is expressed on brain cells including astrocytes
and microglial cells (30–32).
CAFFEINE
Back et al. found reduced cerebral myelination following hypoxia
in mice (33). This hypomyelination was related to abnormal oligo-
dendrocyte lineage progression and reduced progenitor pool. Ven-
triculomegaly was reduced and myelination enhanced in hypoxia-
exposed neonatal pups treated with caffeine (33). These observa-
tions support the hypothesis that hypoxia inhibits oligodendrocyte
maturation and that caffeine administration during early postnatal
development may have utility in the prevention of PVL (33).
In a study conducted by Schmidt et al., caffeine therapy for
apnea of prematurity improved survival rates without neuro-
developmental disability at 18–21 months in infants with very low
birth weight (34). However, a recent publication by the same group
(35) did not find a statistically significant neuro-developmental
advantage at 5 years of age. The“caffeine for apnea of prematurity”
trial group found that infants receiving respiratory support
appeared to derive more neuro-developmental benefits from
caffeine (36).
ESTRADIOL
In rat pups with oxidative stress, 17 beta-estradiol (E2) showed sig-
nificant protection against oxygen glucose deprivation induced cell
death in primary oligodendrocytes (37). Moreover, E2 attenuated
the loss of myelin basic protein labeling in rat pups ipsilateral to
carotid ligation. These results suggest a potential role for estrogens
in attenuation of hypoxic–ischemic and oxidative injury to devel-
oping oligodendrocytes and in the prevention of PVL (37). In a
rat pup model, Gerstner et al. showed that E2 produced significant
dose-dependent protection against oxygen-induced apoptotic cell
death in primary oligodendrocytes (38).
INSULIN-LIKE GROWTH FACTOR
Insulin growth factor-1 (IGF-1) has an important role in brain
development and is strongly expressed during recovery after a
hypoxic–ischemic injury. Some of its central actions could be
mediated through the N-terminal tripeptide fragment of IGF-
1: Gly–Pro–Glu (GPE). The neuroprotective properties of local
and systemic GPE given after a moderate injury in the devel-
oping rat brain were evaluated by Sizonenko et al. who found
both local and systemic neuroprotective effect (38). Although the
precise mode of action of GPE is unknown, this study suggests
that local administration of GPE is neuroprotective after brain
injury via modulating glial cells functions through involvement of
inflammatory cytokines and antioxidants (38).
Delayed IGF-1 administration rescues oligodendrocyte prog-
enitors (OPS) from glutamate-induced cell death (38, 39).
Wood et al. demonstrate that IGF-1 prevents caspase 3 activa-
tion in late OPs when administered up to 16 h following exposure
to glutamate (39).
Moreover, late addition of IGF-1 to OPs previously exposed
to toxic levels of glutamate promotes oligodendrocyte maturation
as measured by myelin basic protein expression. Intraventricu-
larly administered IGF-1 retains OPs in the perinatal white matter
after hypoxia–ischemia when given after insult (39). These results
suggest that delayed administration of IGF-1 will rescue OPs in
the immature white matter and promote myelination following
hypoxia–ischemia (39).
Pang et al. tested whether IGF-1 can prevent PVL-like brain
damage induced by LPS in the neonatal rat (40). IGF-1 at a
low dose significantly prevented LPS-induced deleterious effects
without alteration of IL-1beta expression and microglia/astrocytes
activation. On the other hand, the low dose of IGF-1 enhanced
LPS-induced polymorphonuclear (PMN) recruitment and BBB
permeability, and caused intracerebral hemorrhage (40). At higher
doses, co-application of IGF-1 with LPS resulted in a high mor-
tality rate. Brains from the surviving rats showed massive PMN
infiltration and IVH. However, these adverse effects were not
found in rats treated with IGF-1 alone. This study provides
the alarming evidence that in an acute inflammatory condi-
tion, IGF-1 may have severe, harmful effects on the developing
brain (40).
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MELATONIN
Melatonin is neuroprotective in adult models of focal cerebral
ischemia and attenuates white matter cysts in neonatal mice.
Welin et al. found that melatonin attenuates cell death in fetal
brain in association with reduced inflammatory response fol-
lowing intrauterine asphyxia in mid-gestation fetal sheep (41).
Villapol et al. have demonstrated that melatonin promotes myeli-
nation in rat brain model of hypoxia–ischemia by decreasing
white matter inflammation after neonatal stroke (42). In a fetal
sheep model with umbilical cord occlusion, melatonin had anti-
inflammatory effects as it reduced microglial activation (43). The
anti-inflammatory effect of melatonin may be mediated by pre-
venting the translocation of Nuclear Factor Kappa B (NF-κB) to
the nucleus, thus reducing the up-regulation of pro-inflammatory
cytokines (44).
ENDOGENOUS PROTECTORS
Neuregulin (NRG-1) is a polypeptide growth factor, which inter-
sects with inflammatory mechanisms. Dammann et al. outlined
NRG-1 involvement in perinatal brain damage and suggested it as
a potential target for intervention (45). An increasing body of evi-
dence indicates that NRG-1 and its receptors influence the growth
and maturation of immature oligodendrocytes (45–47).
Since damage to developing oligodendrocytes is a likely patho-
genetic factor in diffuse perinatal WMD, the effects of NRG-1 on
developing oligodendrocytes deserve the attention of those who
want to prevent WMD and its consequences. In the brain, the
neuroprotective effect of NRG-1 exposure prior to middle cere-
bral artery occlusion is accompanied by a prominent reduction in
microglia activation and interleukin-1 mRNA expression, indicat-
ing a down-regulation of peri-infarct inflammation by NRG-1
(46). The hypothesis that NRG might have anti-inflammatory
and anti-oxidative properties in the brain is further supported
by the finding that recombinant human NRG attenuates the pro-
duction of superoxide and nitrite by stimulated microglial cells
(46). Therefore, indirect involvement of the NRG signaling in
established protective pathways might be one avenue for the devel-
opment of improved protection strategies. Thus, NRG-1 might be
an endogenous protector in perinatal brain injury (47). NRG-1
might qualify as a potential target for exogenous indirect or even
direct neuroprotective intervention (46).
GENETIC REGULATION OF INFLAMMATORY PROCESSES
Since inflammatory mediators play a dual role in cell death and
survival there are trials to reveal the genes, which control these
processes. A number of immune-related genes, which are involved
in the expression of proteins involved in the inflammatory process,
were described. One example is NF-κB. This is a transcription fac-
tor that regulates expression of genes involved in inflammation,
cell survival, and apoptosis. It enhances brain damage by stimu-
lation of cytokine production. It can be considered as a nuclear
component of the cell’s inflammatory response NF-κB inducing
kinase (NIK) appears to be one component of the signaling cascade
initiated by pro-inflammatory cytokines, such as tumor necro-
sis factor-α, lymphotoxin-β, and interleukin-1 (47). Nijboer et al.
published a study in which they used the NF-κB inhibitor in rats
and found that it has a significant neuroprotective effect. In this
study, brain damage was reduced by more than 80% with a ther-
apeutic window of at least 6 h and involves down-regulation of
apoptotic molecules (48).
Still, much research is required for further understanding of
the potential therapeutic role of these results.
THERAPEUTIC HYPOTHERMIA
Therapeutic hypothermia in full term infants with a hypoxic–
ischemic injury became common and essential practice (49–
53). In a recent Cochrane review (52), Jacobs et al. reported
that there was evidence from 11 randomized controlled tri-
als (N = 1505 infants) that therapeutic hypothermia is benefi-
cial in term and late preterm newborns with hypoxic–ischemic
encephalopathy. Cooling reduced mortality without increasing
major disability in survivors. The benefits of cooling on survival
and neurodevelopment outweigh the short-term adverse effects.
They concluded hypothermia should be instituted in term and
late preterm infants with moderate-to-severe hypoxic–ischemic
encephalopathy if identified before 6 h of age.
CONCLUSION
As the evidence for the essential role of inflammation in the
pathogenesis of perinatal white matter injury accumulates, exam-
ining therapeutic and preventive options is crucial. Although we
are far from suggesting that there is one “magic silver bullet” in
preventing or treating causes of early brain injury, some of the
interventions presented may qualify as potential neuroprotective
agents.
The goal is that these interventions will minimize brain injury,
thus decreasing mortality and long-term neurological morbidity
in term and preterm infants.
REFERENCES
1. Dammann O, Durum S, Leviton A. Do white cells matter in white matter
damage? Trends Neurosci (2001) 24(6):320–4. doi:10.1016/S0166-2236(00)
01811-7
2. Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter injury of prematurity.
Arch Dis Child Fetal Neonatal Ed (2008) 93(2):F153–61. doi:10.1136/adc.2006.
108837
3. Berger I, Peleg O, Ofek-Shlomai N. Inflammation and early brain injury in term
and preterm infants. Isr Med Assoc J (2012) 14(5):318–23.
4. Leviton A, Dammann O, Durum SK. The adaptive immune response in neona-
tal cerebral white matter damage. Ann Neurol (2005) 58(6):821–8. doi:10.1002/
ana.20662
5. Okazaki K, Nishida A, Kato M, Kozawa K, Uga N, Kimura H. Elevation
of cytokine concentrations in asphyxiated neonates. Biol Neonate (2006)
89(3):183–9. doi:10.1159/000089180
6. Perlman JM. Summary proceedings from the neurology group on hypoxic-
ischemic encephalopathy. Pediatrics (2006) 117(3 Pt 2):S28–33.
7. Tam EW, Haeusslein LA, Bonifacio SL, Glass HC, Rogers EE, Jeremy RJ, et al.
Hypoglycemia is associated with increased risk for brain injury and adverse
neurodevelopmental outcome in neonates at risk for encephalopathy. J Pediatr
(2012) 161(1):88–93. doi:10.1016/j.jpeds.2011.12.047
8. Wu YW, Escobar GJ, Grether JK, Croen LA, Greene JD, Newman TB. Chorioam-
nionitis and cerebral palsy in term and near-term infants. JAMA (2003)
290(20):2677–84. doi:10.1001/jama.290.20.2677
9. Fahey JO. Clinical management of intra-amniotic infection and chorioamnioni-
tis: a review of the literature. J Midwifery Womens Health (2008) 53(3):227–35.
doi:10.1016/j.jmwh.2008.01.001
10. O’Shea TM, Dammann O. Antecedents of cerebral palsy in very low-birth weight
infants. Clin Perinatol (2000) 27(2):285–302. doi:10.1016/S0095-5108(05)
70022-1

























































Ofek-Shlomai and Berger Intervention reducing inflammatory brain injury
11. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early
postnatal dexamethasone treatment and increased incidence of cerebral palsy.
Arch Dis Child Fetal Neonatal Ed (2000) 83(3):F177–81. doi:10.1136/fn.83.3.
F177
12. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticos-
teroids for preventing chronic lung disease in preterm infants. Cochrane Data-
base Syst Rev (2010) (1):CD001146. doi:10.1002/14651858.CD001146.pub3
13. Benders MJ, Groenendaal F, van Bel F, Ha Vinh R, Dubois J, Lazeyras F,
et al. Brain development of the preterm neonate after neonatal hydrocor-
tisone treatment for chronic lung disease. Pediatr Res (2009) 66(5):555–9.
doi:10.1203/PDR.0b013e3181b3aec5
14. Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B,
et al. Neurodevelopmental and growth impairment among extremely low-
birth-weight infants with neonatal infection. JAMA (2004) 292(19):2357–65.
doi:10.1001/jama.292.19.2357
15. Lechpammer M, Manning SM, Samonte F, Nelligan J, Sabo E, Talos
DM, et al. Minocycline treatment following hypoxic/ischaemic injury attenuates
white matter injury in a rodent model of periventricular leucomalacia. Neu-
ropathol Appl Neurobiol (2008) 34(4):379–93. doi:10.1111/j.1365-2990.2007.
00925.x
16. Filipovic R, Zecevic N. Neuroprotective role of minocycline in co-cultures
of human fetal neurons and microglia. Exp Neurol (2008) 211(1):41–51.
doi:10.1016/j.expneurol.2007.12.024
17. Gork AS, Ehrenkranz RA, Bracken MB. Continuous infusion versus intermit-
tent bolus doses of indomethacin for patent ductus arteriosus closure in symp-
tomatic preterm infants. Cochrane Database Syst Rev (2008) (1):CD006071.
doi:10.1002/14651858.CD006071.pub2
18. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al.
Long-term effects of indomethacin prophylaxis in extremely-low-birth-
weight infants. N Engl J Med (2001) 344(26):1966–72. doi:10.1056/
NEJM200106283442602
19. Miller SP, Mayer EE, Clyman RI, Glidden DV, Hamrick SE, Barkovich AJ.
Prolonged indomethacin exposure is associated with decreased white mat-
ter injury detected with magnetic resonance imaging in premature new-
borns at 24 to 28 weeks’ gestation at birth. Pediatrics (2006) 117(5):1626–31.
doi:10.1542/peds.2005-1767
20. Girard S, Sebire H, Brochu ME, Briota S, Sarret P, Sebire G. Postnatal administra-
tion of IL-1Ra exerts neuroprotective effects following perinatal inflammation
and/or hypoxic-ischemic injuries. Brain Behav Immun (2012) 26(8):1331–9.
doi:10.1016/j.bbi.2012.09.001
21. Nold MF, Mangan NE, Rudloff I, Cho SX, Shariatian N, Samarasinghe TD, et al.
Interleukin-1 receptor antagonist prevents murine bronchopulmonary dyspla-
sia induced by perinatal inflammation and hyperoxia. Proc Natl Acad Sci U S A
(2013) 110(35):14384–9. doi:10.1073/pnas.1306859110
22. Sifringer M, Genz K, Brait D, Brehmer F, Lober R, Weichelt U, et al. Erythropoi-
etin attenuates hyperoxia-induced cell death by modulation of inflammatory
mediators and matrix metalloproteinases. Dev Neurosci (2009) 31(5):394–402.
doi:10.1159/000232557
23. Mohamad O,Chen D,Zhang L,Hofmann C,Wei L,Yu SP. Erythropoietin reduces
neuronal cell death and hyperalgesia induced by peripheral inflammatory pain
in neonatal rats. Mol Pain (2011) 7:51. doi:10.1186/1744-8069-7-51
24. Liu W, Shen Y, Plane JM, Pleasure DE, Deng W. Neuroprotective potential of
erythropoietin and its derivative carbamylated erythropoietin in periventricular
leukomalacia. Exp Neurol (2011) 230(2):227–39. doi:10.1016/j.expneurol.2011.
04.021
25. Juul S, Felderhoff-Mueser U. Epo and other hematopoietic factors. Semin Fetal
Neonatal Med (2007) 12(4):250–8. doi:10.1016/j.siny.2007.01.015
26. Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neu-
rons and improves neurobehavioral outcomes in juvenile rats after neona-
tal hypoxia-ischemia. Pediatr Res (2005) 58(2):297–301. doi:10.1203/01.PDR.
0000169971.64558.5A
27. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, et al. Erythropoietin improved
neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pedi-
atrics (2009) 124(2):e218–26. doi:10.1542/peds.2008-3553
28. Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses
of erythropoietin and developmental outcomes in preterm infants. Pediatrics
(2009) 124(4):e681–7. doi:10.1542/peds.2008-2701
29. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Warten-
berg K, et al. Recombinant human erythropoietin in the treatment of acute
ischemic stroke. Stroke (2009) 40(12):e647–56. doi:10.1161/STROKEAHA.109.
564872
30. Fan X, Kavelaars A, Heijnen CJ, Groenendaal F, van Bel F. Pharmacological
neuroprotection after perinatal hypoxic-ischemic brain injury. Curr Neurophar-
macol (2010) 8(4):324–34. doi:10.2174/157015910793358150
31. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU. Erythropoi-
etin and erythropoietin receptors in human CNS neurons, astrocytes, microglia,
and oligodendrocytes grown in culture. J Neuropathol Exp Neurol (2001)
60(4):386–92.
32. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with
decreased inflammatory mediators after erythropoietin administration. Stroke
(2005) 36(8):1672–8. doi:10.1161/01.STR.0000173406.04891.8c
33. Back SA, Craig A, Luo NL, Ren J, Akundi RS, Ribeiro I, et al. Protective effects of
caffeine on chronic hypoxia-induced perinatal white matter injury. Ann Neurol
(2006) 60(6):696–705. doi:10.1002/ana.21008
34. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Long-
term effects of caffeine therapy for apnea of prematurity. N Engl J Med (2007)
357(19):1893–902. doi:10.1056/NEJMoa073679
35. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV,
et al. Survival without disability to age 5 years after neonatal caffeine ther-
apy for apnea of prematurity. JAMA (2012) 307(3):275–82. doi:10.1001/jama.
2011.2024
36. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, et al. Caffeine
for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr (2010)
156(3):382–7. doi:10.1016/j.jpeds.2009.09.069
37. Gerstner B, Lee J, DeSilva TM, Jensen FE, Volpe JJ, Rosenberg PA.
17beta-estradiol protects against hypoxic/ischemic white matter damage in
the neonatal rat brain. J Neurosci Res (2009) 87(9):2078–86. doi:10.1002/jnr.
22023
38. Sizonenko SV, Sirimanne ES, Williams CE, Gluckman PD. Neuroprotec-
tive effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate,
in the immature rat brain after hypoxic-ischemic injury. Brain Res (2001)
922(1):42–50. doi:10.1016/S0006-8993(01)03148-1
39. Wood TL, Loladze V, Altieri S, Gangoli N, Levison SW, Brywe KG, et al. Delayed
IGF-1 administration rescues oligodendrocyte progenitors from glutamate-
induced cell death and hypoxic-ischemic brain damage. Dev Neurosci (2007)
29(4–5):302–10. doi:10.1159/000105471
40. Pang Y, Zheng B, Campbell LR, Fan LW, Cai Z, Rhodes PG. IGF-1 can either
protect against or increase LPS-induced damage in the developing rat brain.
Pediatr Res (2010) 67(6):579–84. doi:10.1203/PDR.0b013e3181dc240f
41. Welin AK, Svedin P, Lapatto R, Sultan B, Hagberg H, Gressens P, et al. Mela-
tonin reduces inflammation and cell death in white matter in the mid-gestation
fetal sheep following umbilical cord occlusion. Pediatr Res (2007) 61(2):153–8.
doi:10.1203/01.pdr.0000252546.20451.1a
42. Villapol S, Fau S, Renolleau S, Biran V, Charriaut-Marlangue C, Baud
O. Melatonin promotes myelination by decreasing white matter inflamma-
tion after neonatal stroke. Pediatr Res (2011) 69(1):51–5. doi:10.1203/PDR.
0b013e3181fcb40b
43. Carloni S, Perrone S, Buonocore G, Longini M, Proietti F, Balduini W. Melatonin
protects from the long-term consequences of a neonatal hypoxic-ischemic brain
injury in rats. J Pineal Res (2008) 44(2):157–64. doi:10.1111/j.1600-079X.2007.
00503.x
44. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX. Melatonin and its relation to
the immune system and inflammation. Ann N Y Acad Sci (2000) 917:376–86.
doi:10.1111/j.1749-6632.2000.tb05402.x
45. Dammann O, Bueter W, Leviton A, Gressens P, Dammann CE. Neuregulin-1: a
potential endogenous protector in perinatal brain white matter damage. Neona-
tology (2008) 93(3):182–7. doi:10.1159/000111119
46. Xu Z, Jiang J, Ford G, Ford BD. Neuregulin-1 is neuroprotective and attenu-
ates inflammatory responses induced by ischemic stroke. Biochem Biophys Res
Commun (2004) 322(2):440–6. doi:10.1016/j.bbrc.2004.07.149
47. Dimayuga FO, Ding Q, Keller JN, Marchionni MA, Seroogy KB, Bruce-Keller AJ.
The neuregulin GGF2 attenuates free radical release from activated microglial
cells. J Neuroimmunol (2003) 136(1–2):67–74. doi:10.1016/S0165-5728(03)
00003-1
48. Nijboer CH, Heijnen CJ, Groenendaal F, May MJ, van Bel F, Kavelaars A. Strong
neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia
involves apoptotic mechanisms but is independent of cytokines. Stroke (2008)
39(7):2129–37. doi:10.1161/STROKEAHA.107.504175

























































Ofek-Shlomai and Berger Intervention reducing inflammatory brain injury
49. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al.
Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med
(2009) 361(14):1349–58. doi:10.1056/NEJMoa0900854
50. Chalak LF, Sanchez PJ, Adams-Huet B, Laptook AR, Heyne RJ, Rosenfeld
CR. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy
and outcomes in newborns receiving hypothermia therapy. J Pediatr (2014)
164(3):468–74.e1. doi:10.1016/j.jpeds.2013.10.067
51. Takenouchi T,Cuaycong M,Ross G,Engel M,Perlman JM. Chain of Brain Preser-
vation – a concept to facilitate early identification and initiation of hypothermia
to infants at high risk for brain injury. Resuscitation (2010) 81(12):1637–41.
doi:10.1016/j.resuscitation.2010.08.001
52. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling
for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst
Rev (2013) 1:CD003311. doi:10.1002/14651858.CD003311.pub3
53. Azzopardi D, Brocklehurst P, Edwards D, Halliday H, Levene M, Thoresen M,
et al. The TOBY Study. Whole body hypothermia for the treatment of perinatal
asphyxial encephalopathy: a randomised controlled trial. BMC Pediatr (2008)
8:17. doi:10.1186/1471-2431-8-17
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 10 November 2013; paper pending published: 22 November 2013; accepted:
27 March 2014; published online: 09 April 2014.
Citation: Ofek-Shlomai N and Berger I (2014) Inflammatory injury to the neonatal
brain – what can we do? Front. Pediatr. 2:30. doi: 10.3389/fped.2014.00030
This article was submitted to Child Health and Human Development, a section of the
journal Frontiers in Pediatrics.
Copyright © 2014 Ofek-Shlomai and Berger . This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, pro-
vided the original author(s) or licensor are credited and that the original publi-
cation in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pediatrics | Child Health and Human Development April 2014 | Volume 2 | Article 30 | 6
